title: Poly-(L-lactic acid) and citric acid-crosslinked gelatin composite matrices as a drug-eluting stent coating material with endothelialization, antithrombogenic, and drug release properties.
abstract: Biodegradable composite matrices comprising poly-(L-lactic acid) (PLLA) and citric acid-crosslinked alkali-treated gelatin (AlGelatin) with endothelialization, antithrombogenic, and drug release properties were prepared. The characterization of composite matrices with various mixing ratios was performed by evaluating their swelling ratio, endothelial cell culture, antithrombogenic tests, and drug release behavior. Tamibarotene (Am80), which specifically inhibits smooth muscle cell proliferation, was employed as the drug. The swelling ratio of composite matrices decreased as the PLLA content decreased. The number of endothelial cells cultured on the surfaces of composite matrices was maximal at the PLLA/AlGelatin-TSC ratio of 80/20. Antithrombogenic tests revealed that the levels of platelets and fibrin network formation decreased as the AlGelatin-TSC content increased. The Am80 release test indicated that the release rate decreased as PLLA content increased. Using the resulting composite matrix, Am80-eluting stents possessing a smooth surface and a coating thickness of ∼15 μm were successfully obtained. Am80 was continuously released from the resulting stent at ∼40%, up to 28 days without burst release. Therefore, Am80-eluting stent with its antithrombogenic and endothelialization properties has great potential for clinical use.
authors.affiliation: Biomaterials Unit, Nano-Life Field, International Center for Materials Nanoarchitectonics (MANA), National Institute for Materials Science (NIMS) 1-1 Namiki, Tsukuba, Ibaraki 305-0044, Japan.
authors.forename: Motoki
authors.initials: M
authors.lastname: Inoue
authors.forename: Makoto
authors.initials: M
authors.lastname: Sasaki
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Katada
authors.forename: Katsuhito
authors.initials: K
authors.lastname: Fujiu
authors.forename: Ichiro
authors.initials: I
authors.lastname: Manabe
authors.forename: Ryozo
authors.initials: R
authors.lastname: Nagai
authors.forename: Tetsushi
authors.initials: T
authors.lastname: Taguchi
mesh_terms: D000818:Animals; D001565:Benzoates / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D049109:Cell Proliferation / Q000187:drug effects; D019343:Citric Acid / Q000737:chemistry*; D020770:Compomers / Q000737:chemistry* / Q000494:pharmacology*; D003432:Cross-Linking Reagents; D003692:Delayed-Action Preparations; D054855:Drug-Eluting Stents; D004730:Endothelium, Vascular / Q000502:physiology*; D005343:Fibrinolytic Agents / Q000737:chemistry / Q000494:pharmacology*; D005780:Gelatin / Q000737:chemistry*; D061307:Human Umbilical Vein Endothelial Cells / Q000187:drug effects; D066298:In Vitro Techniques; D019344:Lactic Acid / Q000737:chemistry*; D008297:Male; D008855:Microscopy, Electron, Scanning; D046529:Microscopy, Electron, Transmission; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D051381:Rats; D017208:Rats, Wistar; D013388:Succinimides / Q000737:chemistry; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D013927:Thrombosis / Q000517:prevention & control
chemical_list: D001565:Benzoates; D020770:Compomers; D003432:Cross-Linking Reagents; D003692:Delayed-Action Preparations; D005343:Fibrinolytic Agents; D013388:Succinimides; D013764:Tetrahydronaphthalenes; C061133:tamibarotene; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019343:Citric Acid; D019344:Lactic Acid; D005780:Gelatin